title: Drug-induced macrophage autophagy in atherosclerosis: for better or worse?
abstract: Autophagy is a reparative, life-sustaining process by which cytoplasmic components are sequestered in double membrane vesicles and degraded upon fusion with lysosomal compartments. Mice with a macrophage-specific deletion of the essential autophagy gene Atg5 develop plaques with increased apoptosis and oxidative stress as well as enhanced plaque necrosis. This finding indicates that basal autophagy in macrophages is anti-apoptotic and present in atherosclerotic plaques to protect macrophages against various atherogenic stressors. However, autophagy is impaired in advanced stages of atherosclerosis and its deficiency promotes atherosclerosis in part through activation of the inflammasome. Because basal autophagy can be intensified selectively in macrophages by specific drugs such as mammalian target of rapamycin (mTOR) inhibitors or Toll-like receptor 7 (TLR7) ligands, these drugs were recently tested as potential plaque stabilizing compounds. Stent-based delivery of the mTOR inhibitor everolimus promotes a stable plaque phenotype, whereas local administration of the TLR7 ligand imiquimod stimulates inflammation and plaque progression. Therefore, more drugs capable of inducing autophagy should be tested in plaque macrophages to evaluate the feasibility of this approach. Given that drug-induced macrophage autophagy is associated with pro-inflammatory responses due to cytokine release, induction of postautophagic necrosis or activation of phagocytes after clearance of the autophagic corpse, cotreatment with anti-inflammatory compounds may be required. Overall, this review highlights the pros and cons of macrophage autophagy as a drug target for plaque stabilization.
authors.affiliation: Laboratory of Physiopharmacology, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium. wim.martinet@ua.ac.be
authors.forename: Wim
authors.initials: W
authors.lastname: Martinet
authors.forename: Inge
authors.initials: I
authors.lastname: De Meyer
authors.forename: Stefan
authors.initials: S
authors.lastname: Verheye
authors.forename: Dorien M
authors.initials: DM
authors.lastname: Schrijvers
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Timmermans
authors.forename: Guido R Y
authors.initials: GR
authors.lastname: De Meyer
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D001343:Autophagy / Q000187:drug effects*; D016207:Cytokines / Q000096:biosynthesis; D000068338:Everolimus; D006801:Humans; D000077271:Imiquimod; D008264:Macrophages / Q000187:drug effects* / Q000502:physiology; D051379:Mice; D058226:Plaque, Atherosclerotic / Q000139:chemically induced / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000502:physiology; D051199:Toll-Like Receptor 7 / Q000502:physiology
chemical_list: D000634:Aminoquinolines; D016207:Cytokines; D051199:Toll-Like Receptor 7; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D000077271:Imiquimod; D020123:Sirolimus